HR陽性/HER2陰性早期乳がんにおける補助的なCDK4/6阻害剤の投与中の再発の管理:新たな課題
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
PubMedで要約を見る
まとめ
この要約は機械生成です。補助的なサイクリン依存キナーゼ4およびキナーゼ6阻害剤 (CDK4/ 6i) は,乳がんの早期再発を減少させます. しかし,一部の患者はまだ遠隔転移を発症し,耐性疾患に対する新しい戦略を必要とします.
科学分野
- 腫瘍学
- 薬理学について
- 臨床医学
背景
- 現在,サイクリン依存キナーゼ4および6阻害剤 (CDK4/ 6i) は,高リスクホルモン受容体陽性,ヒト表皮成長因子受容体2陰性早期乳がんの標準補助療法となっている.
- 有効性にもかかわらず,注意すべき部分の患者は,補助的なCDK4/ 6i治療中にまたはその直後に遠隔転移を経験する.
研究 の 目的
- 早期乳がん患者の臨床的課題に対処するため,補助的なCDK4/ 6i療法にもかかわらず再発した.
- 耐性疾患の新興集団に対する管理と治療の方法を提案する.
主な方法
- 補助的なCDK4/6i中にまたは後に再発パターンを特定する重要な試験データのレビュー.
- 耐性疾患と再発後の治療の有効性に関する既存の文献の分析
- 実用的な臨床管理戦略の開発
主要な成果
- 補助的なCDK4/ 6iで再発率の有意な減少が観察されているが,約10%の患者は依然として再発する.
- この患者グループの生物学的メカニズムと最適な再発後の治療法に関するデータは限られている.
- 補助的なCDK4/ 6i中に発生する再発を管理するための実用的なアプローチが提案されています.
結論
- 補助的なCDK4/ 6iを投与した後に再発した患者は,治療の有効性と生物学的根拠がほとんど不明で,臨床的な課題が増加しています.
- この特定の患者集団を調査する専用の研究と臨床試験が緊急に必要です.
- 耐性疾患の患者の治療結果を最適化するためのさらなる研究を待つ間,実用的な管理戦略は不可欠です.
関連する概念動画
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...